Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur’s Dengue Vaccine, Dengvaxia®

December 22, 2015 — The Philippines yesterday became the first Asian country to approve Sanofi Pasteur’s dengue vaccine, Dengvaxia®, marking the second time in less than one month that a dengue vaccine has been licensed for use in a country.

Regional Dengue Symposium Addresses Today’s Challenges in Dengue Control

RIO DE JANEIRO, BRAZIL — November 3, 2015 — More than one hundred public health experts and stakeholders gathered today in Rio de Janeiro, Brazil, for the First Regional Dengue Symposium, led by the Pan American Health Organization (PAHO), the Sabin Vaccine Institute (Sabin) and the Dengue Vaccine Initiative (DVI).

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.

Pages